Pharma Giant Merck Makes $2 Billion Bet On A Dallas Based Cancer Drug Developer

Peloton Therapeutics is a clinical-stage company that's developing medications for patients who have cancer or other life-threatening conditions. The company was founded in 2011 by UT Southwestern biochemists and molecular geneticists, and launched with an $11 million grant from the Cancer Prevention Research Institute of Texas, the state cancer-fighting agency.

Pharma giant Merck makes $2 billion bet on a Dallas-based cancer drug developer
Why This "Worst Deal" Could Work
The 25 Best Blue-Chip Stocks for 2019 (According to Hedge Funds)
After disappointing 2016, new drug approvals roared back to life in 2017
Drug in Combination with Merck's Blockbuster Keytruda Nearly Doubles Response Rate
UT Southwestern looks to lure cancer researchers with $14 million in state grants
Merck pulls promising late-stage drug trial
Biotech stocks rally as investors bet on the next big tie-up
STING fever is sweeping through the cancer immunotherapy world
AstraZeneca strikes $8.5B cancer deal, disappoints on trial results